<DOC>
	<DOC>NCT01040312</DOC>
	<brief_summary>The purpose of this study is to examine the correlation between UGT1A1 genotypes and the safety of CPT-11 plus platinum analogues (cisplatin, carboplatin and nedaplatin) regimens for patients with lung cancer, cervical cancer, ovarian cancer and gastric cancer.</brief_summary>
	<brief_title>An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Small cell lung cancer, nonsmall cell lung cancer, cervical cancer, ovarian cancer and gastric cancer Patients with UGT1A1 genotype *1/*6, *1/*28, *6/*6, *28/*28 and *6/*28 Patients to receiving CPT11 plus platinum analogues (cisplatin, carboplatin and nedaplatin) regimens (with or without molecular targeted agents) Contraindication of CPT11 ECOG PS 34</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>UGT1A1, irinotecan</keyword>
</DOC>